Shares of Teladoc, Inc. (NYSE:TDOC) have received an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $37.30.

Several research analysts recently weighed in on TDOC shares. Cowen and Company restated an “outperform” rating and set a $39.00 price target (up previously from $36.00) on shares of Teladoc in a research report on Thursday, August 3rd. KeyCorp began coverage on shares of Teladoc in a report on Wednesday, May 17th. They issued an “overweight” rating and a $37.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $32.00 price objective on shares of Teladoc in a report on Friday, July 14th. TheStreet downgraded shares of Teladoc from a “c-” rating to a “d” rating in a report on Monday, July 3rd. Finally, BidaskClub downgraded shares of Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th.

In other Teladoc news, VP Mark Hirschhorn sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $27.70, for a total value of $2,770,000.00. Following the completion of the transaction, the vice president now owns 80,887 shares of the company’s stock, valued at approximately $2,240,569.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jason N. Gorevic sold 5,600 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $29.57, for a total transaction of $165,592.00. Following the completion of the transaction, the chief executive officer now directly owns 823,861 shares of the company’s stock, valued at approximately $24,361,569.77. The disclosure for this sale can be found here. Insiders sold a total of 207,186 shares of company stock valued at $6,122,950 in the last three months. 5.94% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of TDOC. State Street Corp boosted its position in shares of Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock valued at $6,309,000 after buying an additional 9,146 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock valued at $581,000 after buying an additional 1,759 shares in the last quarter. First Mercantile Trust Co. acquired a new position in shares of Teladoc during the first quarter valued at approximately $175,000. Russell Investments Group Ltd. acquired a new position in shares of Teladoc during the first quarter valued at approximately $583,000. Finally, Wells Fargo & Company MN boosted its position in shares of Teladoc by 43.8% in the first quarter. Wells Fargo & Company MN now owns 543,568 shares of the health services provider’s stock valued at $13,589,000 after buying an additional 165,435 shares in the last quarter. 94.51% of the stock is owned by institutional investors.

Shares of Teladoc (NYSE:TDOC) traded up 1.63% during midday trading on Friday, hitting $31.20. The stock had a trading volume of 512,598 shares. Teladoc has a 52-week low of $14.00 and a 52-week high of $36.90. The firm has a 50 day moving average price of $33.60 and a 200-day moving average price of $27.80. The stock’s market cap is $1.77 billion.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter last year, the company earned ($0.38) EPS. The firm’s revenue for the quarter was up 68.3% on a year-over-year basis. Equities analysts predict that Teladoc will post ($1.46) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teladoc, Inc. (TDOC) Receives $37.30 Consensus Target Price from Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/15/teladoc-inc-tdoc-receives-37-30-consensus-target-price-from-analysts.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.